Bispecific and human disease-related anti-keratin rabbit monoclonal antibodies

被引:14
作者
Tao, GZ
Nakamichi, I
Ku, NO
Wang, J
Frolkis, M
Gong, XS
Zhu, WM
Pytela, R
Omary, MB
机构
[1] Vet Affairs Med Ctr, Palo Alto, CA 94304 USA
[2] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA
[3] Epitom Inc, Burlingame, CA 94010 USA
关键词
intermediate filaments; phosphorylation; bispecific antibodies; rabbit monoclonal antibody; molecular mimicry; K8; glycine-61; keratin mutations;
D O I
10.1016/j.yexcr.2005.11.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Rabbit antibodies may have favorable properties compared to mouse antibodies, including high affinities and better antigen recognition. We used a biochemical and reverse immunologic approach to generate and characterize rabbit anti-phospho-keratin and anti-keratin monoclonal antibodies (MAb). Human keratins 8 and 18 (K8/K18) were used as immunogens after isolation from cells pretreated with okadaic acid or pervanadate to promote Ser/Thr or Tyr hyperphosphorylation, respectively. Selected rabbit MAb were tested by immunofluorescence staining, immunoprecipitation, and 2-dimensional gels. Keratin phospho and non-phospho-mutants were used for detailed characterization of two unique antibodies. One antibody recognizes a K8 G61-containing epitope, an important epitope given that K8 G61C is a frequent mutation in human liver diseases. This antibody binds K8 that is not phosphorylated on S73, but its binding is ablated by G61 but not S73 mutation. The second antibody is bispecific in that it simultaneously recognizes two epitopes: one phospho (K8 pS431) conformation-independent and one non-phospho conformation-dependent, with both epitopes residing in the K8 tail domain. Therefore, a reverse immunologic and biochemical approach is a viable too] for generating versatile rabbit MAb for a variety of cell biologic applications including the potential identification of physiologic phosphorylation sites. Published by Elsevier Inc.
引用
收藏
页码:411 / 422
页数:12
相关论文
共 45 条
[1]  
CHOU CF, 1992, J BIOL CHEM, V267, P3901
[2]   'Hard' and 'soft' principles defining the structure, function and regulation of keratin intermediate filaments [J].
Coulombe, PA ;
Omary, MB .
CURRENT OPINION IN CELL BIOLOGY, 2002, 14 (01) :110-122
[3]   Cytoplasmic intermediate filaments revealed as dynamic and multipurpose scaffolds [J].
Coulombe, PA ;
Wong, P .
NATURE CELL BIOLOGY, 2004, 6 (08) :699-706
[4]  
Das D, 2005, METH MOLEC MED, V109, P329
[5]   Mallory bodies revisited [J].
Denk, H ;
Stumptner, C ;
Zatloukal, K .
JOURNAL OF HEPATOLOGY, 2000, 32 (04) :689-702
[6]  
Feng L, 1999, J CELL SCI, V112, P2081
[7]   A structural scaffolding of intermediate filaments in health and disease [J].
Fuchs, E ;
Cleveland, DW .
SCIENCE, 1998, 279 (5350) :514-519
[8]   Intermediate filament associated proteins [J].
Green, KJ ;
Böhringer, M ;
Gocken, T ;
Jones, JCR .
FIBROUS PROTEINS: COILED-COILS, COLLAGEN AND ELASTOMERS, 2005, 70 :143-+
[9]   Veterinary sources of nonrodent monoclonal antibodies: Interspecific and intraspecific hybridomas [J].
Groves, DJ ;
Morris, BA .
HYBRIDOMA, 2000, 19 (03) :201-214
[10]   Novel approaches for targeted cancer therapy [J].
Guillemard, V ;
Saragovi, HU .
CURRENT CANCER DRUG TARGETS, 2004, 4 (04) :313-326